Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06VCC
|
|||
| Former ID |
DIB003614
|
|||
| Drug Name |
REGN-421
|
|||
| Synonyms |
Dll4 antibody; Dll4-Fc; Delta-like ligand 4 antibody (VelociSuite), Regeneron, sanofi-aventis
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 1 | [1] | |
| Company |
Regeneron pharmaceuticals; sanofi us
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Delta-like protein 4 (DLL4) | Target Info | . | [2] |
| KEGG Pathway | Notch signaling pathway | |||
| NetPath Pathway | Notch Signaling Pathway | |||
| Panther Pathway | Angiogenesis | |||
| Notch signaling pathway | ||||
| Pathway Interaction Database | Notch signaling pathway | |||
| Reactome | Activated NOTCH1 Transmits Signal to the Nucleus | |||
| Constitutive Signaling by NOTCH1 PEST Domain Mutants | ||||
| Constitutive Signaling by NOTCH1 t(7 | ||||
| M1580_K2555) Translocation Mutant | ||||
| Constitutive Signaling by NOTCH1 HD Domain Mutants | ||||
| Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | ||||
| NOTCH2 Activation and Transmission of Signal to the Nucleus | ||||
| WikiPathways | Notch Signaling Pathway | |||
| Signaling by NOTCH3 | ||||
| Signaling by NOTCH4 | ||||
| Signaling by NOTCH1 | ||||
| Signaling by NOTCH2 | ||||
| Notch Signaling Pathway | ||||
| Neural Crest Differentiation | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00871559) A Multiple-Ascending-Dose Study of the Safety and Tolerability of REGN421(SAR153192) in Patients With Advanced Solid Malignancies. U.S. National Institutes of Health. | |||
| REF 2 | J Clin Oncol 31, 2013 (suppl; abstr 2502). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.